Search results for "gaba"

showing 10 items of 390 documents

Activation of glycine receptors modulates spontaneous epileptiform activity in the immature rat hippocampus

2014

While the expression of glycine receptors in the immature hippocampus has been shown, no information about the role of glycine receptors in controlling the excitability in the immature CNS is available. Therefore, we examined the effect of glycinergic agonists and antagonists in the CA3 region of an intact corticohippocampal preparation of the immature (postnatal days 4-7) rat using field potential recordings. Bath application of 100 μM taurine or 10 μM glycine enhanced the occurrence of recurrent epileptiform activity induced by 20 μM 4-aminopyridine in low Mg(2+) solution. This proconvulsive effect was prevented by 3 μM strychnine or after incubation with the loop diuretic bumetanide (10 …

TaurinePhysiologyTaurineGlycinePharmacologyHippocampuschemistry.chemical_compoundNeuroscience: Development/Plasticity/RepairReceptors GlycinemedicineAnimalsRats WistarReceptorGlycine receptorCells CulturedEpilepsyChemistryGABAA receptorStrychnineRatsBiochemistrynervous systemAnimals NewbornGlycineGabazineAnticonvulsantsBumetanidemedicine.drug
researchProduct

Natural selection constrains personality and brain gene expression differences in Atlantic salmon (Salmo salar).

2015

ABSTRACT In stream-spawning salmonid fishes there is a considerable variation in the timing of when fry leave the spawning nests and establish a feeding territory. The timing of emergence from spawning nests appears to be related to behavioural and physiological traits, e.g. early emerging fish are bolder and more aggressive. In the present study, emerging Atlantic salmon (Salmo salar L.) alevins were sorted into three fractions: early, intermediate and late emerging. At the parr stage, behaviour, stress responses, hindbrain monoaminergic activity and forebrain gene expression were explored in fish from the early and late emerging fractions (first and last 25%). The results show that when s…

Time FactorsPhysiologymedia_common.quotation_subjectSalmo salarZoologyGene ExpressionNerve Tissue ProteinsAquatic ScienceEpendyminmedicineJuvenileAnimalsSalmoSelection GeneticMolecular BiologyEcology Evolution Behavior and Systematicsmedia_commonNatural selectionbiologyBehavior AnimalAggressionEcologyBoldnessBrainAquatic animalbiology.organism_classificationReceptors GABA-AInsect ScienceForebrainReceptor Serotonin 5-HT1Abiology.proteinAnimal Science and Zoologymedicine.symptomStress PsychologicalThe Journal of experimental biology
researchProduct

Antiepileptic Drugs for the Treatment of Chronic and Episodic Cluster Headache: A Review.

2007

Cluster headache needs to be rapidly diagnosed and effectively managed, as the individual headache attacks that are characteristic of this disorder are excruciatingly painful and debilitating. Preventive therapies are necessary to reduce the frequency of attacks during the cluster period. However, preventive therapy for this disorder is limited by a lack of controlled evidence of efficacy and the potential for systemic toxicity. Recent progress has been made in understanding both the pathophysiological mechanisms underlying cluster headache and the mechanisms of action of the antiepileptic drug class for the treatment of primary headache syndromes. Newly available preliminary clinical trial…

Topiramatemedicine.medical_specialtyCyclohexanecarboxylic AcidsGabapentinmedicine.drug_classCluster HeadacheFructoseNeurological disorderDisease clusterReceptors GABATopiramatemedicineHumansAminesIntensive care medicinegamma-Aminobutyric AcidValproic Acidbusiness.industryValproic AcidCluster headacheMood stabilizermedicine.diseaseClinical trialTreatment OutcomeNeurologyAnesthesiaAnticonvulsantsNeurology (clinical)Gabapentinbusinessmedicine.drugHeadache: The Journal of Head and Face Pain
researchProduct

Pharmacologic Approaches to CDH: Evidence and Outcomes

2018

Chronic daily headache (CDH) is a highly prevalent condition that severely affects patient’s lives. Most patients with CDH experience chronic migraine (CM). The management of these patients is complex and includes acute and preventive pharmacological treatment. In CDH, the use of acute medication should be restricted to avoid the risk of medication-overuse headache. However, the use of preventive medication should be considered in all patients with CDH. There are few studies investigating the role of preventives in CDH, and the majority have CM. Topiramate and onabotulinumtoxinA are the only two drugs with proved scientific evidence in the prevention of CM. There are other neuromodulators, …

Topiramatemedicine.medical_specialtyFluoxetineeducation.field_of_studyGabapentinbusiness.industryPopulationVenlafaxineChronic MigraineInternal medicinemedicineAmitriptylinebusinesseducationFlunarizinemedicine.drug
researchProduct

Transcriptional Mechanisms of Proneural Factors and REST in Regulating Neuronal Reprogramming of Astrocytes

2015

Summary Direct lineage reprogramming induces dramatic shifts in cellular identity, employing poorly understood mechanisms. Recently, we demonstrated that expression of Neurog2 or Ascl1 in postnatal mouse astrocytes generates glutamatergic or GABAergic neurons. Here, we take advantage of this model to study dynamics of neuronal cell fate acquisition at the transcriptional level. We found that Neurog2 and Ascl1 rapidly elicited distinct neurogenic programs with only a small subset of shared target genes. Within this subset, only NeuroD4 could by itself induce neuronal reprogramming in both mouse and human astrocytes, while co-expression with Insm1 was required for glutamatergic maturation. Cu…

Transcription GeneticRepressorNerve Tissue ProteinsCell fate determinationBiologyDNA-binding proteinArticleMiceGlutamatergicBasic Helix-Loop-Helix Transcription FactorsGeneticsAnimalsHumansPromoter Regions GeneticTranscription factorCells CulturedNeuronsCell BiologyCellular ReprogrammingMolecular biologyCell biologyDNA-Binding ProteinsRepressor ProteinsASCL1Astrocytesembryonic structuresMolecular MedicineGABAergicReprogrammingTranscription FactorsCell Stem Cell
researchProduct

Perfluoroktānsulfoskābes (PFOS) un tās atvasinājumu bioakumulācija Latvijas upju baseinu apgabalos

2020

Bakalaura darbs ,,Perfluoroktānsulfoskābes (PFOS) un tās atvasinājumu bioakumulācija Latvijas upju baseinu apgabalos’’ ar mērķi noteikt PFOS koncentrācijas Baltijas jūras piekrastes asaros Perca fluviatilis, un noskaidrot iespējamo upju pienesi kā PFOS avotu Baltijas jūrā, salīdzinot ar sateces baseinu biotas koncentrācijām. Darbā ir apkopota informācija par PFOS un tās atvasinājumu īpašībām, pārneses iespējām dabā, akumulēšanos dzīvajos organismos un veikts pasaules pētījumu apskats. Pētnieciskajā daļā tika iegūtas piekrastes asaru aknu PFOS koncentrācijas, veikta iekšzemes ūdeņu analīze pa upju baseinu apgabaliem un rezultātu salīdzināšana. PFOS un tās atvasinājumi konstatēti visos biotas…

Vides zinātneBaltijas jūraupju baseinu apgabaliasarisPFOS un tās atvasinājumiPerca fluviatilis
researchProduct

Electrophysiological and morphological properties of Cajal–Retzius cells with different ontogenetic origins

2010

International audience; The different origins of Cajal-Retzius cells (CRc) as well as their diverse molecular profile suggest that this cell type may represent different neuronal subpopulations. In order to investigate whether CRc from different origins show distinct functional or morphological characteristics we used transgenic Dbx1(cre);ROSA26(YFP) mice in which two subpopulations of CRc, originating from the septum and ventral pallium (VP) at the pallial-subpallial border (PSB), were permanently labeled by yellow fluorescent protein (YFP) expression. Electrophysiological properties of YFP(+) and YFP(-) CRc were investigated by whole-cell patch-clamp recordings, while a thorough somatoden…

Yellow fluorescent proteinCell typePatch-Clamp TechniquesNeurogenesisAction PotentialsGlutamic AcidMice Transgenicmacromolecular substancesReceptors N-Methyl-D-AspartateMembrane PotentialsMice03 medical and health scienceschemistry.chemical_compoundOrgan Culture Techniques0302 clinical medicineBiocytinAnimalsCell LineagePatch clampCell Shapegamma-Aminobutyric AcidImage Cytometry030304 developmental biologyCerebral CortexNeurons0303 health sciencesbiologyStem CellsGeneral NeurosciencefungiCell DifferentiationDendritesHyperpolarization (biology)digestive system diseasesCell biologyLuminescent ProteinsElectrophysiologynervous systemchemistrybiology.proteinGABAergic[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]DBX1Nerve NetExcitatory Amino Acid Antagonists030217 neurology & neurosurgeryNeuroscience
researchProduct

Age-dependent epileptic encephalopathy associated with an unusual co-occurrence of ZEB2 and SCN1A variants.

2020

Mowat-Wilson syndrome is a genetic disorder associated with a variable phenotype including peculiar facial features associated with intellectual disability, epilepsy, language impairment, and multiple congenital anomalies caused by heterozygous mutation of the ZEB2 gene. The ZEB2 protein is a complex transcription factor that encompasses multiple functional domains that interact with the regulatory regions of target genes including those involved in brain development. Recently, it has been documented that ZEB2 regulates the differentiation of interneuron progenitors migrating from the medial ganglionic eminence to cortical layers by repression of the Nkx2-1 homeobox transcription factor. It…

ZEB2genotype-phenotype correlationSettore MED/38 - Pediatria Generale E SpecialisticaSettore M-PSI/08 - Psicologia ClinicaIntellectual DisabilityHumansMowat-Wilson syndromeEEGgenotype-phenotype correlationSCN1AHirschsprung DiseaseEEGChildGenetic Association StudiesZEB2Zinc Finger E-box Binding Homeobox 2EpilepsyEEG; epilepsy; GABAergic interneurons; genotype-phenotype correlation; Mowat-Wilson syndrome; SCN1A; ZEB2FaciesElectroencephalographySettore MED/39 - Neuropsichiatria InfantileGABAergic interneuronsMowat-Wilson syndromeepilepsyNAV1.1 Voltage-Gated Sodium ChannelGABAergic interneuronsMicrocephalySettore MED/26 - NeurologiaFemaleEpileptic disorders : international epilepsy journal with videotape
researchProduct

GABAA-receptor Subtypes: Clinical Efficacy and Selectivity of Benzodiazepine Site Ligands

1997

The main inhibitory neurotransmitter receptor of the brain, the gamma-aminobutyric acid type A receptor (GABA[A]), mediates the actions of several classes of clinically important drugs, such as benzodiazepines, barbiturates and general anaesthetics. This review summarizes the current knowledge on how classical benzodiazepines and novel nonbenzodiazepine compounds act on the benzodiazepine site of GABA(A) receptors and on their clinical pharmacology related to anxiolytic, sedative, hypnotic and cognitive effects or side-effects. Partial agonism, receptor subtype selectivity and novel binding sites are discussed as possible strategies to develop new drugs with fewer adverse effects than are s…

ZolpidemPyridinesmedicine.drug_classNonbenzodiazepinePharmacologyLigandsAnxiolyticHypnoticBenzodiazepines03 medical and health sciences0302 clinical medicineReceptors GABAmedicineHumansHypnotics and Sedatives030304 developmental biologyNeurotransmitter Agents0303 health sciencesBenzodiazepineBinding SitesGABAA receptorbusiness.industryGeneral Medicine3. Good healthZolpidemMechanism of actionSedativemedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugAnnals of Medicine
researchProduct

Zaleplon displays a selectivity to recombinant GABAA receptors different from zolipdem, zopiclone and benzodiazepines

1999

A chemically heterogeneous group of compounds acts at the benzodiazepine (BZ) recognition site of the γ-aminobutyric acid type A (GABAA) receptor complex. Whereas most 1,4-BZs recognize all GABAA/BZ receptors with similar affinity, other compounds differentiate between the large number of native GABAA receptors which assemble from the more than 14 known subunits. Here we describe the in vitro binding properties of the BZs lorazepam and Ro 15-4513 plus the three hypnotics zaleplon, zolpidem and zopiclone to eight receptors subtypes. Lorazepam fits well into the general shceme for other 1,4-BZs with respect to its receptor subtype selectivity in spite of its clinically different use. Zaleplon…

ZopicloneZolpidemReceptor complexBenzodiazepineGABAA receptorChemistrymedicine.drug_classStereochemistryGeneral NeurosciencePharmacologyHypnoticZaleplonmedicineReceptormedicine.drugNeuroscience Research Communications
researchProduct